Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson’s disease: Post-hoc analyses from a large 54-week trial

Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson’s disease: Post-hoc analyses from a large 54-week trial

Introduction: Carbidopa/levodopa enteral suspension (CLES) previously demonstrated reduction in total daily OFF from baseline by over 4 hours in advanced Parkinson’s disease patients across 54 weeks. Evidence on CLES’s long-term effectiveness on patterns of motor-symptom control throughout the day r...

Full description

Bibliographic Details
Main Authors: Rajesh Pahwa, Jason Aldred, Aristide Merola, Niodita Gupta, Emi Terasawa, Viviana Garcia-Horton, David R. Steffen, Prasanna L. Kandukuri, Yanjun Bao, Omar Ladhani, Connie H. Yan, Vivek Chaudhari, Stuart H. Isaacson
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:Clinical Parkinsonism & Related Disorders
Subjects:
Carbidopa/levodopa enteral suspension
Carbidopa/levodopa intestinal gel
Dyskinesia
Parkinson’s disease
Duopa
Duodopa
Online Access:http://www.sciencedirect.com/science/article/pii/S2590112522000524

Similar Items

Similar Items